KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial.

Chin Med J (Engl) · 2025-Jun-20 · PMID 39385327

Panel A提取完成待 EXE 对齐验证

Time to deterioration in pain

Figure 4 Kaplan–Meier plots of TTD in mBPI-SF worst pain with increased analgesic use in (A) cohort A and (B) cohort B. TTD in pain was estimated using combined data from mBPI-SF and analgesic use, where deterioration in pain was defined as an increase of ≥2 points in mBPI-SF “worst pain” score from baseline (previously established as the minimally important difference), [26] or an increase of ≥1 level of analgesic drug class from baseline. † HR, stratified HR from Cox proportional hazard model and 95% CI by nature of disease; ‡ Log-rank stratified nominal P value (two-sided) for comparison of treatment vs. placebo + NSAI; § HR – stratified HR from Cox proportional hazard model and 95% CI by nature of disease; ¶ Log-rank stratified nominal P value (two-sided) for comparison of treatment vs . placebo + fulvestrant. 95% CI: 95% confidence interval; HR: Hazard ratio; mBPI-SF: Modified Brief Pain Inventory-Short Form; NSAI: Non-steroidal aromatase inhibitor; TTD: Time to deterioration; TTSD: Time to sustained deterioration.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-22T18:31:30+00:00